Entropy Technologies LP Purchases New Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Entropy Technologies LP purchased a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,300 shares of the company’s stock, valued at approximately $214,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. abrdn plc acquired a new stake in Travere Therapeutics during the fourth quarter valued at approximately $6,829,000. Jennison Associates LLC acquired a new stake in Travere Therapeutics during the fourth quarter valued at approximately $14,222,000. China Universal Asset Management Co. Ltd. boosted its holdings in Travere Therapeutics by 23.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,206 shares of the company’s stock valued at $317,000 after purchasing an additional 3,494 shares in the last quarter. Baader Bank Aktiengesellschaft acquired a new stake in Travere Therapeutics during the fourth quarter valued at approximately $192,000. Finally, R Squared Ltd acquired a new stake in Travere Therapeutics during the fourth quarter valued at approximately $53,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Scotiabank lifted their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a report on Wednesday. Piper Sandler lifted their price objective on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. Evercore ISI boosted their target price on Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday. Barclays boosted their target price on Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Finally, HC Wainwright boosted their target price on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $27.77.

Insiders Place Their Bets

In other Travere Therapeutics news, SVP William E. Rote sold 2,437 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the sale, the senior vice president now owns 83,170 shares in the company, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Sandra Calvin sold 12,090 shares of the company’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00. Following the sale, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at $1,005,164.10. The trade was a 18.04 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 218,425 shares of company stock valued at $4,674,259. 3.75% of the stock is currently owned by corporate insiders.

Travere Therapeutics Stock Down 3.4 %

NASDAQ:TVTX opened at $22.91 on Friday. The stock’s fifty day moving average price is $19.22 and its two-hundred day moving average price is $16.10. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $25.29. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -5.04 and a beta of 0.72.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.